Sutimlimab Cad denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sutimlimab for Cold Agglutinin Disease — Non-Formulary

A non-formulary denial means sutimlimab is not included in BCBS's drug formulary for your specific plan, and therefore requires a formulary exception to be covered. For ultra-rare diseases like cold agglutinin disease (CAD), formulary exclusions are common — the drug may simply not appear on a standard tier list because the covered population is very small. This does not mean coverage is impossible; it means you must formally request a formulary exception and demonstrate that no formulary alternative is clinically appropriate for this patient.

## Why This Denial Is Appealable

Most BCBS plans — and federal law under ACA §2719 — require a meaningful formulary exception process. An exception should be granted when: (1) every formulary alternative is medically contraindicated, clinically inappropriate, or has already been tried and failed; or (2) no formulary alternative treats the patient's specific condition. For CAD, sutimlimab's targeted mechanism addresses a specific complement pathway; if no formulary drug shares that mechanism or the same FDA-approved indication for CAD, the exception argument is strong. The ACA also grants external review rights for non-formulary denials when medical necessity is at issue.

## Federal Appeal Framework

• Formulary exception request: Submit simultaneously with or immediately before the formal appeal. This is often a separate, faster administrative track and may resolve the denial without a full appeal.
• Internal appeal (Level 1): File within the plan's deadline. Request the list of formulary alternatives BCBS identified and the clinical basis for considering them equivalent.
• External review (ACA §2719): After a final internal denial, request independent external review within approximately four months. Applies when non-formulary status is tied to a medical necessity determination.
• ERISA §503: Self-funded plan members may request the complete administrative record and challenge the formulary tier structure.
• Expedited review: Available when clinical urgency is documented.

## Documentation to Gather

• Confirmed CAD diagnosis with laboratory and clinical documentation
• BCBS's formulary (obtain the current plan year formulary and identify every drug listed in the relevant therapeutic category)
• Treating hematologist's letter explaining why each formulary alternative is clinically inadequate, inappropriate, or inapplicable to CAD
• Prior treatment history: any formulary alternatives already tried, with dates and documented outcomes
• FDA prescribing information for sutimlimab confirming its specific approved indication
• Documentation of disease severity to support urgency if requesting expedited review

## Criteria-Mapping Structure

Obtain BCBS's formulary exception criteria from the plan benefit document or by calling the pharmacy benefits line. For each criterion (typically: formulary alternative tried and failed; formulary alternative contraindicated; no formulary alternative for the condition), provide the specific chart documentation. If no formulary drug is approved for CAD, state that directly and support it with the FDA labeling for each comparator drug. A concise, evidence-linked formulary exception letter from the hematologist is often the most effective document in this appeal.